Brickell Biotech Reports Second Quarter 2022 Financial Results and Provides Corporate Update
11 août 2022 16h05 HE
|
Brickell Biotech, Inc.
Phase 1 study of BBI-02 progressing well and expect to initiate MAD part of the study next month On track to report SAD and MAD topline results from BBI-02 Phase 1 study by early 2023 ...
Brickell Biotech to Report Second Quarter 2022 Financial Results and Provide a Corporate Update on August 11, 2022
02 août 2022 16h05 HE
|
Brickell Biotech, Inc.
BOULDER, Colo., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing...
Brickell Biotech Regains Compliance with Nasdaq Minimum Bid Price Requirement
20 juil. 2022 08h00 HE
|
Brickell Biotech, Inc.
BOULDER, Colo., July 20, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing...
Brickell Biotech to Participate at William Blair Biotech Focus Conference 2022
06 juil. 2022 08h00 HE
|
Brickell Biotech, Inc.
BOULDER, Colo., July 06, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by...
Brickell Biotech Announces 1-For-45 Reverse Stock Split
01 juil. 2022 14h02 HE
|
Brickell Biotech, Inc.
BOULDER, Colo., July 01, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by...
Brickell Biotech Doses First Subject in Phase 1 Study of DYRK1A Inhibitor BBI-02
19 mai 2022 08h00 HE
|
Brickell Biotech, Inc.
– BBI-02 is a potential first-in-class, oral DYRK1A inhibitor with strong preclinical validation and broad potential to treat debilitating autoimmune and inflammatory diseases – – Topline...
Brickell Biotech Reports First Quarter 2022 Financial Results and Provides Corporate Update
12 mai 2022 16h01 HE
|
Brickell Biotech, Inc.
Completed sale of sofpironium bromide to Botanix Pharmaceuticals for up to $9 million in upfront and potential near-term regulatory milestone payments, $168 million in potential future regulatory and...
Brickell Biotech to Report First Quarter 2022 Financial Results and Provide a Corporate Update on May 12, 2022
05 mai 2022 16h01 HE
|
Brickell Biotech, Inc.
BOULDER, Colo., May 05, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by...
Brickell Biotech Announces Adjournment of Annual Meeting of Stockholders
03 mai 2022 16h02 HE
|
Brickell Biotech, Inc.
Meeting adjourned to May 17, 2022 at 10 a.m. MT Brickell encourages all stockholders of record on March 7, 2022 who have not yet voted to do so by 11:59 p.m. Eastern Time on May 16, 2022 BOULDER,...
Brickell Biotech Announces Sale of Sofpironium Bromide to Botanix Pharmaceuticals
03 mai 2022 16h01 HE
|
Brickell Biotech, Inc.
Deal includes up to $9 million in upfront and potential near-term regulatory milestone payments, $168 million in potential future regulatory and sales milestone payments, plus tiered earn out payments...